METHOD FOR PROMOTING MYOCARDIAL REGENERATION AND USES THEREOF
The present invention provides a method for promoting myocardial regeneration in a subject. Additionally, the present invention provides a method for promoting myocardial cell and tissue regeneration in a subject. The present invention is further directed to the use of GM-284 in promoting myocardial tissue regeneration in a subject. Finally, the present invention provides a method for treating a myocardial infarction in a subject in need of such treatment.
1 . A method for promoting myocardial regeneration in a subject, comprising the step of administering to the subject an amount of GM284 effective to promote myocardial regeneration in the subject.
2 . The method of claim 1 , wherein the myocardial regeneration is promoted in the subject by promoting myocardial tissue regeneration.
3 . The method of claim 2 , wherein the myocardial tissue regeneration in the subject is promoted by regenerating myocardial cells.
4 . The method of claim 1 , wherein the subject is a mammal.
5 . The method of claim 4 , wherein the mammal is a human.
6 . The method of claim 1 , wherein the amount of GM-284 is between about 1 mg/kg and about 10 mg/kg.
7 . The method of claim 6 , wherein the amount of GM-284 is about 5 mg/kg.
8 . The method of claim 1 , wherein the amount of GM-284 is between about 0.1 pM and about 5 mM.
9 . The method of claim 8 , wherein the amount of GM-284 is between about 5 pM and about 1.5 mM.
10 . The method of claim 1 , wherein the GM-284 is administered to the subject by oral administration, parenteral administration, sublingual administration, topical administration, transdermal administration, or osmotic pump.
11 . A method for promoting myocardial tissue regeneration in a subject, comprising the step of administering to the subject an amount of GM-284 effective to promote myocardial tissue regeneration in the subject.
12 . The method of claim 11 , wherein the myocardial tissue regeneration in the subject is promoted by promoting myocardial cell regeneration in the subject.
13 . The method of claim 12 , wherein the myocardial cell regeneration is promoted in the region of a myocardial infarction in the subject.
14 . The method of claim 13 , wherein the subject is a mammal.
15 . The method of claim 13 , wherein the mammal is a human.
16 . The method of claim 13 , wherein the amount of GM-284 is between about 1 mg/kg and about 10 mg/kg.
17 . The method of claim 16 , wherein the amount of GM-284 is about 5 mg/kg.
18 . The method of claim 13 , wherein the amount of GM-284 is between about 0.1 pM and about 5 mM.
19 . The method of claim 18 , wherein the amount of GM-284 is between about 5 pM and about 1.5 mM.
20 . The method of claim 13 , wherein the GM-284 is administered to the subject by oral administration, parenteral administration, sublingual administration, topical administration, transdermal administration, or osmotic pump.
21 . A method for promoting myocardial cell regeneration, comprising contacting myocardial tissue with an amount of GM-284 effective to promote myocardial cell regeneration.
22 . The method of claim 21 , wherein the contacting is effected in vitro.
23 . The method of claim 21 , wherein the contacting is effected in vivo in a subject.
24 . The method of claim 23 , wherein the myocardial cell regeneration promotes healing of a myocardial infarction in the subject.
25 . The method of claim 23 , wherein the contacting is effected in vivo in a subject by administering GM-284 to the subject.
26 . The method of claim 25 , wherein the GM-284 is administered to the subject by oral administration, parenteral administration, sublingual administration, topical administration, transdermal administration, or osmotic pump.
27 . The method of claim 25 , wherein the subject is a human.
28 . The method of claim 27 , wherein the human has a myocardial infarction.
29 . The method of claim 26 , wherein the amount of the immunophilin ligand is between about 0.1 pM and about 5 mM.
30 . The method of claim 29 , wherein the amount, of die immunophilin ligand is between about 5 pM and about 1.5 mM.
31 . A method for treating a myocardial infarction in a subject in need of treatment, comprising administering to the subject an amount, of GM-284 effective to treat the myocardial infarction in the subject.